Please use this identifier to cite or link to this item: https://doi.org/10.1097/01.tp.0000166921.14670.33
Title: Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation
Authors: Vathsala, A 
Ona, ET
Tan, SY
Suresh, S
Lou, HX
Casasola, CBC
Wong, HC
Machin, D
Chiang, GSC
Danguilan, RA
Calne, R 
Keywords: Adolescent
Adult
Aged
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Cyclosporine
Female
Graft Rejection
Humans
Immunotherapy
Kidney
Kidney Function Tests
Kidney Transplantation
Male
Middle Aged
Time Factors
Issue Date: 27-Sep-2005
Publisher: Ovid Technologies (Wolters Kluwer Health)
Citation: Vathsala, A, Ona, ET, Tan, SY, Suresh, S, Lou, HX, Casasola, CBC, Wong, HC, Machin, D, Chiang, GSC, Danguilan, RA, Calne, R (2005-09-27). Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80 (6) : 765-774. ScholarBank@NUS Repository. https://doi.org/10.1097/01.tp.0000166921.14670.33
Abstract: Background. A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). Methods. Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n=20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n=10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. Results. Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, -92 to -34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%-97%) were steroid free. Conclusion. These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx. Copyright © 2005 by Lippincott Williams & Wilkins.
Source Title: Transplantation
URI: https://scholarbank.nus.edu.sg/handle/10635/229456
ISSN: 0041-1337
1534-6080
DOI: 10.1097/01.tp.0000166921.14670.33
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Randomised Trial of Alemtuzumab - CAMPATH-1H_TRANSPLANTATION.pdf1.14 MBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

100
checked on Oct 1, 2022

Page view(s)

27
checked on Sep 29, 2022

Download(s)

3
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.